A Study of LY3471851 in Participants With Psoriasis

• Status: Completed
• Trial end date: 2021-07-21
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to learn more about the safety and side effects of LY3471851 when given by injection just under the skin to participants with psoriasis. The study will last up to 48 weeks and may include up to 23 visits to the study center.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Collaborator: Nektar Therapeutics

Criteria

Inclusion Criteria:

• Have a confirmed diagnosis of psoriasis for at least 6 months

• Have active psoriasis plaques according to study- specific criteria

• Be willing and able to undergo skin biopsies

Exclusion Criteria:

• Have received certain topical medications for psoriasis within 14 days prior to baseline

• Have received certain systemic medications for psoriasis within 4 weeks prior to baseline

• Have received LY3471851 previously